Capmatinib generic drug price

Capmatinib (Capmatinib) is a small molecule kinase inhibitor that belongs to the category of targeted therapy drugs. Its main function is to specifically inhibit MET (Mesenchymal Epithelial Transition Factor) kinase activity, thereby targeting METexon14skipping mutation non-small cell lung cancer (NSCLC) patients, blocking abnormal signaling pathways and inhibiting tumor growth and spread.

Capmatinib is not yet available in China, so patients cannot purchase it domestically yet and need to purchase it through overseas channels. Currently, there are Hong Kong version of original drugs and foreign original drugs and generic drugs. The price of Hong Kong version of original drugs is about 35,000 yuan. The overseas original drugs are mainly European version of original drugs, and the price is more than 50,000 yuan, so original drugs are still relatively expensive.

The generic drugs marketed abroad are much cheaper, mainly Lao generic drugs, which cost around 3,000 to 4,000 yuan, and the ingredients of the original drugs and generic drugs are basically the same.

METkinase is a receptor tyrosine kinase that participates in a variety of cell biological processes, including cell growth, migration, angiogenesis, etc. In some cases, abnormal activation of METkinase is closely related to the occurrence and development of cancer. The development of capmatinib aims to specifically intervene in the biological process of MET exon 14 skipping mutant NSCLC by inhibiting the activity of METkinase.

The clinical application of capmatinib is mainly for patients with NSCLC carrying METexon14 skipping mutations. This variant is relatively rare in lung cancer patients, but is related to a special subgroup of lung cancer that is insensitive to traditional treatments. Because capmatinib can precisely interfere with the signaling of abnormal activation of MET kinase, it has shown significant efficacy in this patient group and improved the success rate of treatment for patients with this specific gene mutation.